Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Starling OncologySTLN +5.56%56 Earnings Yield (Joel Greenblatt) % is -9.43% as of Mar. 2026. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Starling Oncology ranks worse than 79.88% on this metric.
Starling Oncology's Enterprise Value for the quarter that ended in Mar. 2026 was $381.5 Mil.
Starling Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-36.0 Mil. Starling Oncology's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -9.43%.
The historical rank and industry rank for Starling Oncology's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
STLN'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -75.77 Med: -15.05 Max: 4.73
Current: -6.13
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Starling Oncology was 4.73%. The lowest was -75.77%. And the median was -15.05%.
STLN's Earnings Yield (Joel Greenblatt) % is ranked worse than 79.88% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 3.55
vs STLN: -6.13
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Starling Oncology's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Starling Oncology Earnings Yield (Joel Greenblatt) % Related Terms
Starling Oncology Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Starling Oncology's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Starling Oncology's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starling Oncology Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Starling Oncology's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Starling Oncology's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Starling Oncologys Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Starling Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.0 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -9.43% mean?
Starling Oncology (STLN) has a Earnings Yield (Joel Greenblatt) % of -9.43% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Starling Oncology and its competitors. According to the industry distribution chart, Starling Oncology ranks #544 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 79.9%.
Is Starling Oncology's Earnings Yield (Joel Greenblatt) % too high?
Starling Oncology's current Earnings Yield (Joel Greenblatt) % is -9.43%. Based on the distribution chart, Starling Oncology ranks #544 out of 681 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Earnings Yield (Joel Greenblatt) % compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Starling Oncology ranks #544 out of 681 companies for Earnings Yield (Joel Greenblatt) %. This places Starling Oncology in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.55, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Starling Oncology and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starling Oncology's current Earnings Yield (Joel Greenblatt) % is -9.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -9.43%. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Starling Oncology (STLN), the current Earnings Yield (Joel Greenblatt) % is -9.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starling Oncology (STLN) Overvalued in 2026?
Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued.
The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29.
GuruFocus considers Starling Oncology to be Significantly Overvalued.
Key valuation signals for STLN:
Earnings Yield (Joel Greenblatt) %: -9.43%
GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for STLN
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STLN has been successfully added to your 
